– CANADA, Toronto – FSD Pharma Inc. (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company today announced the appointments of Dr. Lakshmi Kotra (Ph.D.) and Joseph Romano to its Board of Directors, effective November 25, 2022.
“We welcome Dr. Kotra and Mr. Romano to the Board of Directors. Their combined wealth of knowledge and experience we believe will be valuable,” said Founder, Interim CEO & Executive Co-Chairman, Anthony Durkacz.
Effective at the same time was the resignation of Fernando Cugliari from the Board of Directors.
About Dr. Lakshmi P. Kotra
Dr. Lakshmi Kotra received his Ph.D. in Pharmacy from the University of Georgia under Prof. David Chu’s supervision and completed postdoctoral training at Wayne State University under Prof. Shahriar Mobashery’s supervision. He joined the Faculty of Pharmacy, at the University of Toronto in 2000, and the University Health Network in 2006, where he led a research group and drug discovery program with multiple portfolios. An academic entrepreneur, Dr. Kotra has contributed to several important drug discovery and development projects, including metabolic disorders, neurodegenerative and immunological disorders, anti-HIV drugs, antibacterials, and antimalarials. He has authored/co-authored over 130 publications and delivered over 140 scientific talks internationally. Dr. Kotra is the recipient of several awards for his accomplishments, including the Julia Levy Award in 2021 from the Society of Chemical Industry Canada in recognition of his substantial contribution to the successful commercialization of innovation in Canada in the field of biomedical science and engineering. In addition to Lucid Psycheceuticals Inc., he co-founded WinSanTor Biosciences, a San Diego, CA-based company developing treatments for peripheral neuropathies, and CannScience Innovations focused on medical cannabis and cannabinoids. Dr. Kotra transcends early and clinical development incorporating commercial and regulatory vision for efficient drug development and commercialization with solid leadership. Dr. Kotra has been serving the Company as CEO of its wholly-owned subsidiary, Lucid, upon completion of the Company’s acquisition of Lucid in September 2021.
About Joseph L. Romano
Mr. Romano is the founding member of the Romano Law Firm. He has dedicated his law career to helping victims of serious personal injury and motor vehicle accidents.
A graduate of Osgoode Hall Law School, Mr. Romano has successfully appeared at all levels of court in Ontario, Canada.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly-owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for treating inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
For more information: https://fsdpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.